Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-09-05 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for Simcere Pharmaceutical Group Limited. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document includes confirmations of compliance with listing rules and legal requirements related to share repurchases. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure focused on share repurchase activity and changes in capital structure. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-09-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2024. It details movements in issued shares, treasury shares, share options, warrants, convertibles, and other share-related agreements. It includes specific data on share repurchases, cancellations, and restricted share units granted. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is a regulatory disclosure about share capital movements and share repurchases. It is not a financial report like an annual or interim report, nor is it a management discussion or earnings release. It is a regulatory filing related to share capital movements and share repurchase disclosures. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7742 characters) and detailed content confirm it is not a brief announcement but a formal regulatory filing.
2024-09-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details share repurchase transactions, including dates, prices, and quantities. The document includes confirmations about compliance with listing rules and legal requirements related to share repurchases. The content is focused on reporting share repurchase activity and changes in share capital, which aligns with the category for company buying back or selling its own shares. The document is substantive and detailed, not merely an announcement or certification, and does not fit other categories like capital raising or regulatory filings. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2024-09-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares for Simcere Pharmaceutical Group Limited. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details share repurchase transactions, including dates, prices, and quantities. The document includes confirmations of compliance with listing rules and regulatory requirements. It is a regulatory disclosure about share repurchases and changes in capital structure, not a financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2024-09-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details share repurchase transactions, including dates, prices, and quantities. The document includes confirmations of compliance with listing rules and regulatory requirements. It is a regulatory disclosure about share repurchases and changes in capital structure rather than a financial report or earnings announcement. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, not just an announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is POS with high confidence.
2024-09-02 English
VOLUNTARY ANNOUNCEMENT - BREAKTHROUGH THERAPY DESIGNATION (BTD) OF SANBEXIN SUBLINGUAL TABLETS GRANTED BY THE U.S. FOOD AND DRUG ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the FDA granting Breakthrough Therapy Designation (BTD) for their Sanbexin sublingual tablets. It is an announcement about a regulatory and business development event, not a financial report, earnings release, or management discussion. The document is relatively short (4314 characters) and serves to inform shareholders and investors about a significant business milestone. There is no financial data, no meeting materials, no voting results, no legal proceedings, no capital changes, and no detailed financial or operational report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-09-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.